You have landed on a page of the archived Cochrane Community website. This site is not being maintained or updated.

If you are looking for Cochrane Review evidence, please visit Cochrane’s evidence page.

If you are a Cochrane contributor looking for Community resources, please visit the new Cochrane Community website.

Rivastigmine for Alzheimer's disease (French version)

Warning: Parameter 2 to onepixelout_swftools_flashvars() expected to be a reference, value given in module_invoke() (line 476 of /var/www/archive/includes/module.inc).

To browse Podcasts by topic, please visit the new Cochrane Summaries site here

The use of cholinesterase inhibitors in people with Alzheimer's disease has long been a focus of interest and concern. In this podcast, Jacqueline Birks, a researcher from Oxford, England, reports the results of an updated systematic review studying the benefits and harms of one of these agents, rivastigmine, including a novel mode of percutaneous administration. (French version)

This Podcast also available in: English

Play Now!

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Download [mp3]  | Read Review
library
Updated on: April 30, 2014, 10:41

Comments for improvement or correction are welcome.
Email: web@cochrane.org